IRF4: Immunity. Malignancy! Therapy?
IRF4: Immunity. Malignancy! Therapy?
复制标题
DOI：
10.1158/1078-0432.ccr-08-1845
复制
发表时间：
2009-05-01
期刊：
影响因子：
--
通讯作者：
Staudt LM
中科院分区：
文献类型：
--
作者：
Shaffer AL;Emre NC;Romesser PB;Staudt LM
IRF 4是转录因子IRF家族的成员，在免疫系统的细胞中表达，在那里它从各种受体转导信号以激活或抑制基因表达。IRF 4表达是淋巴样、骨髓样和树突状细胞分化中几个步骤的关键调节因子，包括成熟B细胞分化为分泌抗体的浆细胞。IRF4表达也与许多淋巴恶性肿瘤相关，最近的证据表明在多发性骨髓瘤（浆细胞恶性肿瘤）中起重要作用。干扰IRF4表达对多发性骨髓瘤细胞是致命的，无论其遗传病因如何，使IRF4成为可用于治疗的“阿喀琉斯之踵”。
IRF4, a member of the IRF family of transcription factors, is expressed in cells of the immune system where it transduces signals from various receptors to activate or repress gene expression. IRF4 expression is a key regulator of several steps in lymphoid, myeloid and dendritic cell differentiation, including the differentiation of mature B cells into antibody-secreting plasma cells. IRF4 expression is also associated with many lymphoid malignancies, with recent evidence pointing to an essential role in multiple myeloma, a malignancy of plasma cells. Interference with IRF4 expression is lethal to multiple myeloma cells, irrespective of their genetic etiology, making IRF4 an “Achilles’ heel” that may be exploited therapeutically.